Spyre Therapeutics (SYRE) Change in Intangibles (2025 - 2026)

Spyre Therapeutics (SYRE) reported Change in Intangibles of $30.0 million for Q1 2026, up 328.57% quarter-over-quarter from $7.0 million in Q2 2025.

Spyre Therapeutics (SYRE) Change in Intangibles (2025 - 2026) Analysis & Trends

Spyre Therapeutics has reported Change in Intangibles for 2 years, with the latest figure at $30.0 million in Q1 2026.

For the quarter ending Q1 2026, Change in Intangibles changed N/A year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $37.0 million (changed N/A YoY), and the FY2025 full-year result was $7.0 million, changed N/A from the prior year.
Change in Intangibles for Q1 2026 stood at $30.0 million, up from $7.0 million in the prior quarter.
The five-year high for Change in Intangibles was $30.0 million in Q1 2026, with the low at $7.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Intangibles (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-2.96 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Spyre Therapeutics	6.95 Bn	6.95 Bn	-	30.00 Mn

Download Data